


# Influenza




1



## Historical Perspective — Emergence of Influenza A (H1N1) Viruses

Shanta M. Zimmer, M.D., and Donald S. Burke, M.D.  
N Engl J Med 2009; 361:279-285 | July 16, 2009 | DOI: 10.1056/NEJMr0904322

2




## Historical Perspective — Emergence of Influenza A (H1N1) Viruses

Shanta M. Zimmer, M.D., and Donald S. Burke, M.D.  
N Engl J Med 2009; 361:279-285 | July 16, 2009 | DOI: 10.1056/NEJMr0904322

3


<http://www.cdc.gov/flu/>

## Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS Collaborating Laboratories, National Summary, 2013-14




4

## 2012-2013 season



5

## 2012-2013 season



6

## www.who.int/topics/influenza/

WHO | Influenza

World Health Organization

Health topics

Influenza

Influenza is a viral infection that affects mainly the nose, throat, bronchi and, occasionally, lungs. Infection usually lasts for about a week, and is characterized by sudden onset of high fever, aching muscles, headache and severe malaise, non-productive cough, sore throat and rhinitis.

The virus is transmitted easily from person to person via droplets and small particles produced when infected people cough or sneeze. Influenza tends to spread rapidly in seasonal epidemics.

Most infected people recover within one to two weeks without requiring medical treatment. However, in the very young, the elderly, and those with other serious medical conditions, infection can lead to severe complications of the underlying condition, pneumonia and death.

**General Information**

- Fact sheet on influenza
- Fact sheet on avian influenza
- Influenza news via RSS feed

**Technical information**

- Human infection with avian influenza A(H7N9) virus
- Global Influenza Surveillance and Response System (GISRS)
- Influenza vaccines
- More about influenza

**WHO programmes and activities**

- Global Influenza Programme

7

## www.cdc.gov/flu/about/season

CDC - 2013-2014 Flu Season | Seasonal Influenza (Flu)

CDC Home

Centers for Disease Control and Prevention

CDC 24/7: Saving Lives. Protecting People.™

A-Z Index

Seasonal Influenza (Flu)

2013-2014 Flu Season

Vaccine Selection

What You Should Know

Influenza - Flu Basics

Prevention - Flu Vaccine

Treatment - Antiviral Drugs

Specific Groups

Health Professionals

Resources for Flu Prevention Partners

Flu Activity & Surveillance

FluVaxView Influenza Vaccination Coverage

Avian Flu

Avian Influenza A (H7N9) Virus

Swine Flu

2013-2014 Flu Season

This page provides information about the 2013-2014 influenza season.

- What You Should Know for the 2013-2014 Influenza Season
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-14, MMWR 2013, September 20, 2013 / 62(R07):1-43
- Summary Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2013-14
- Influenza Activity - United States, 2012-13 Season and Composition of the 2013-14 Influenza Vaccine
- 2013-2014 Influenza Vaccine Information Statements (VIS)
- UPDATE: Influenza Activity - United States and Worldwide, May 19-September 28, 2013; MMWR, October 25, 2013 / 62(42):838-842

Email page link

Print page

CDC on Facebook

CDC Flu on Twitter

Get email updates

Subscribe to RSS

Listen to audio/Podcast

View page in:

Español


Health Insurance Marketplace

Marketplace plans cover free flu vaccines.

Fact: People with flu


8

<http://www.google.org/flutrends>




9

## United States Flu Activity




United States: Influenza-like illness (ILI) data provided publicly by the [U.S. Centers for Disease Control](#).


10




11



12



13



14

## Vaccines to prevent influenza in healthy adults

Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E

Published Online: June 4, 2013

Over 200 viruses cause influenza and influenza-like illness which produce the same symptoms (fever, headache, aches and pains, cough and runny noses). Without laboratory tests, doctors cannot tell the two illnesses apart. Both last for days and rarely lead to death or serious illness. At best, vaccines might be effective against only influenza A and B, which represent about 10% of all circulating viruses. Each year, the World Health Organization recommends which viral strains should be included in vaccinations for the forthcoming season.

Authors of this [review](#) assessed all trials that compared vaccinated people with unvaccinated people. The combined results of these trials showed that under ideal conditions (vaccine completely matching circulating viral configuration) 33 healthy adults need to be vaccinated to avoid one set of influenza symptoms. In average conditions (partially matching vaccine) 100 people need to be vaccinated to avoid one set of influenza symptoms. Vaccine use did not affect the number of people hospitalised or working days lost but caused one case of Guillain-Barré syndrome (a major neurological condition leading to paralysis) for every one million vaccinations. Fifteen of the 36 trials were funded by vaccine companies and four had no funding declaration. Our results may be an optimistic estimate because company-sponsored influenza vaccines trials tend to produce results favorable to their products and some of the evidence comes from trials carried out in ideal viral circulation and matching conditions and because the harms evidence base is limited..

15

## Vaccines for preventing seasonal influenza and its complications in people aged 65 or older

Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thoring S, Thomas RE

Published Online: February 17, 2010

Influenza vaccination of elderly individuals is recommended worldwide as people aged 65 and older are at a higher [risk](#) of complications, hospitalisations and deaths from influenza. This [review](#) looked at evidence from experimental and non-experimental studies carried out over 40 years of influenza vaccination. We included 75 studies. These were grouped first according to [study](#) design and then the setting (community or long-term care facilities). The results are mostly based on non-experimental (observational) studies, which are at greater [risk of bias](#), as not many good quality trials were available. Trivalent inactivated vaccines are the most commonly used influenza vaccines. Due to the poor quality of the available evidence, any conclusions regarding the effects of influenza vaccines for people aged 65 years or older cannot be drawn. The public health safety profile of the vaccines appears to be acceptable.

16



## Vaccines for preventing influenza in healthy children

Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E

Published Online: August 15, 2012

Children (< 16 years old) and the elderly (above 65 years old) are the two age groups that appear to have the most complications following an influenza infection. Influenza has a viral origin and often results in an acute respiratory illness affecting the lower or upper parts of the respiratory tract, or both. Viruses are mainly of two subtypes (A or B) and spread periodically during the autumn-winter months. However, many other viruses can also cause respiratory tract illnesses.

Diffusion and severity of the disease could be very different during different epidemics. Efforts to contain epidemic diffusion rely mainly on widespread vaccination. Recent policy from several internationally-recognised institutions, recommend immunisation of healthy children between 6 and 23 months of age (together with their contacts) as a public health measure.

The [review](#) authors found that in children aged from two years, nasal spray vaccines made from weakened influenza viruses were better at preventing illness caused by the influenza virus than injected vaccines made from the killed virus. Neither type was particularly good at preventing 'flu-like illness' caused by other types of viruses. In children under the age of two, the [efficacy](#) of inactivated vaccine was similar to [placebo](#). It was not possible to analyse the safety of vaccines from the studies due to the lack of standardisation in the information given, but very little information was found on the safety of inactivated vaccines, the most commonly used vaccine in young children.

17

## Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions

Thomas RE, Jefferson T, Lasserson TJ

Published Online: July 23, 2013

Older individuals in long-term care institutions (LTCIs) at [risk](#) of influenza may be infected by their healthcare workers. There are no accurate [data](#) on rates of laboratory-proven influenza in healthcare workers. Vaccinating healthcare workers against influenza may reduce infections acquired from this source. Because the signs and symptoms of influenza are similar to those of many other respiratory illnesses, it is important in studies testing the effects of influenza vaccination to prove by laboratory tests which are highly accurate whether residents in LTCIs actually have influenza or another respiratory illness.

Three randomised controlled trials (RCTs) (5896 participants) provided [outcome data](#) meeting our criteria. For [risk of bias](#): [randomisation](#) was at low [risk](#) in two trials and unclear in one; [allocation concealment](#) and [blinding](#) in all three trials was unclear; [incomplete outcome data](#) in one trial was at low [risk](#) and in two at high [risk](#); selective reporting all three trials was at low [risk](#); performance [bias](#) (incomplete influenza vaccination of healthcare workers in the [intervention](#) arms) in all three trials was at high [risk](#). No studies reported on adverse events. Vaccinating healthcare workers who care for those aged 60 or over in LTCIs showed no effect on laboratory-proven influenza or complications (lower respiratory tract infection, hospitalisation or death due to lower respiratory tract illness) in those aged 60 or over resident in LTCIs.

This [review](#) did not find information on other interventions used in conjunction with vaccinating healthcare workers (hand-washing, face masks, early detection of laboratory-proven influenza, quarantine, avoiding new admissions, prompt use of antivirals and asking healthcare workers with an influenza-like illness not to work).

There is no evidence that only vaccinating healthcare workers prevents laboratory-proven influenza or its complications (lower respiratory tract infection, hospitalisation or death due to lower respiratory tract infection) in individuals aged 60 or over in LTCIs and thus no evidence to mandate compulsory vaccination of healthcare workers. Other interventions, such as hand-washing, masks, early detection of influenza with nasal swabs, antivirals, quarantine, restricting visitors and asking healthcare workers with an influenza-like illness not to attend work, might protect individuals over 60 in LTCIs. High-quality randomised controlled trials testing combinations of these interventions are needed.

18

© 2010 American Society for Nutrition

## Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren<sup>1,2,3</sup>

Mitsuyoshi Urashima, Takaaki Segawa, Minoru Okazaki, Mana Kurihara, Yasuyuki Wada, and Hiroyuki Iida

Author Affiliations

Author Notes

Abstract

**Background:** To our knowledge, no rigorously designed clinical trials have evaluated the relation between vitamin D and physician-diagnosed seasonal influenza.

**Objective:** We investigated the effect of vitamin D supplements on the incidence of seasonal influenza A in schoolchildren.


**Design:** From December 2008 through March 2009, we conducted a randomized, double-blind, placebo-controlled trial comparing vitamin D<sub>3</sub> supplements (1200 IU/d) with placebo in schoolchildren. The primary outcome was the incidence of influenza A, diagnosed with influenza antigen testing with a nasopharyngeal swab specimen.

**Results:** Influenza A occurred in 18 of 167 (10.8%) children in the vitamin D<sub>3</sub> group compared with 31 of 167 (18.6%) children in the placebo group [relative risk (RR), 0.58; 95% CI: 0.34, 0.99; *P* = 0.04]. The reduction in influenza A was more prominent in children who had not been taking other vitamin D supplements (RR: 0.36; 95% CI: 0.17, 0.79; *P* = 0.006) and who started nursery school after age 3 y (RR: 0.36; 95% CI: 0.17, 0.78; *P* = 0.005). In children with a previous diagnosis of asthma, asthma attacks as a secondary outcome occurred in 2 children receiving vitamin D<sub>3</sub> compared with 12 children receiving placebo (RR: 0.17; 95% CI: 0.04, 0.73; *P* = 0.006).

**Conclusion:** This study suggests that vitamin D<sub>3</sub> supplementation during the winter may reduce the incidence of influenza A, especially in specific subgroups of schoolchildren. This trial was registered at <https://center.umin.ac.jp> as UMIN000001373.

Received December 17, 2009.  
Accepted February 11, 2010.

19



20

In the month of April there prevailed an influenza essentially different from that which had been observed five years previously.

I know not if the studies that were made of it at that time were correct, or if I am mistaken in my appreciation of the disease. I shall therefore only draw attention to one single point of dissimilarity and leave to my readers the trouble of comparing the others.

In the epidemic of 1782 there was scarcely a third or even a fourth of the inhabitants who were not attacked by a fever presenting all the symptoms of a catarrho-rheumatic fever, though it only lasted seven days. In general they were all affected in the same degree; though there was not danger except to debilitated subjects, to old people, and those suffering from pulmonary consumption.


In the influenza of the present year, on the contrary, nine-tenths scarcely had anything more than slight traces of the malady, without fever; the other tenth, on the contrary, were attacked by fever, and danger was imminent. Patients who had none of the febrile symptoms did not usually seek advice, and were not considered to be affected by the epidemic. It was difficult to observe them, and their symptoms were not perceived by unobservant medical men.

...

*Some Kinds of Continued and Remittent Fevers*

Hufeland's Journal der practischen Arzneykunde. Vol. v. 1798 (written 1789)

21



22

When the influenza endemic in Siberia comes among us, as it does occasionally, when the hot stage has already commenced, camphor is of service, only as a palliative certainly, but an invaluable palliative, seeing that the disease is one of short duration. It should be given in frequent but ever increasing doses, dissolved in water as above described.

It does not shorten the duration of the disease, but renders it much milder, and hence it conducts the disease innocuously to its termination.

*Materia Medica Pura, Camphora*



23

When the influenza endemic in Siberia comes among us, as it does occasionally, when the hot stage has already commenced, camphor is of service, only as a palliative certainly, but an invaluable palliative, seeing that the disease is one of short duration. It should be given in frequent but ever increasing doses, dissolved in water as above described.

It does not shorten the duration of the disease, but renders it much milder, and hence it conducts the disease innocuously to its termination.

*Materia Medica Pura, Camphora*



24

When the influenza endemic in Siberia comes among us, as it does occasionally, when the hot stage has already commenced, camphor is of service, only as a palliative certainly, but an invaluable palliative, seeing that the disease is one of short duration. It should be given in frequent but ever increasing doses, dissolved in water as above described.

It does not shorten the duration of the disease, but renders it much milder, and hence it conducts the disease innocuously to its termination.

(On the other hand, nux vomica, in a single dose, and that the smallest possible, will often remove the disease homoeopathically in a few hours.)

*Materia Medica Pura, Camphora*



(Stychnos) Nux-vomica

25



(Cinnamomum) camphora



(Stychnos) Nux-vomica

26

[GENERALS] INFLUENZA: (125) Acon. aesc. all-c. ant-ar. ant-i. ant-t. apis. arn. ars. ars-i. ars-s-r. arum-d. asc-c. asc-t. aven. bapt. Bell. Brom. bry. calc. ~~camph.~~ camph-br. canch. capp-crc. carb-ac. carb-v. card-m. caust. cent. cham. chel. chin. Chinin-s. cimic. Cinnb. cupr. cupr-ar. cycl. des-ac. dioxi. diphtox. dros. dulc. erio. ery-a. Eucal. eug. Eup-per. euph. euphr. ferr-p. Gels. glon. glyc. Graph. gymno. haff. influ. iod. ip. kali-bi. kali-c. kali-i. kali-s. Kreos. lach. lob-c. lob-p. lob-s. lyc. Lycpr. menth. MERC. merc-c. merc-k-i. Nat-n. nat-s. Nat-sal. **Nux-v.** oci-sa. oscilloc. oxyg. phel. phos. phyt. podo. Psor. puls. pyrog. rad-br. rhus-r. Rhus-t. rumx. sabad. sal-ac. salin. salol. Sang. sangin-n. sanic. sarcol-ac. sarr. seneg. Sil. silphu. spig. spong. squil. stict. still. stram. stry-xyz. sul-i. sulo-ac. Sulph. Thymul. trios. Tub. tub-a. vario. Verat. verat-v. wye. yers. ziz. + (9)

camphor is of service, only as a palliative certainly,  
but an invaluable palliative, seeing that the disease is one of short duration  
It does not shorten the duration of the disease, but renders it much milder ...

27

§100

In the investigation of the symptom complex of epidemic or sporadic diseases, it makes no difference if something similar has ever appeared before under the same or any other name ...



28



§73

...

Since every case of disease in a given epidemic has the same origin, the disease puts all those who have fallen ill into the same kind of disease process.



29

§102


To be sure, all those afflicted by the epidemic at that time have the same disease, flowing from one and the same source.

However, the entire extent of such an epidemic disease and the totality of its symptoms

...

cannot be perceived in a single patient,

but can only be completely abstracted and gathered [inferred] from the sufferings of several patients of different bodily constitutions.



30

§101

It may well be that the physician does not get a perception of the complete image of the epidemic disease with the first case he encounters since each such collective disease only brings the complex of its symptoms to the light of day with the closer observation of several cases.


Meanwhile, the carefully investigating physician can often come so close to the true state, even with the first or second patient, that he becomes alive to the characteristic image of the disease, and then finds a fitting, homeopathically commensurate remedy for it.



31

§102

Upon recording the symptoms of several cases of this kind, the sketch of the disease image becomes more and more complete -



32



§102

Upon recording the symptoms of several cases of this kind, the sketch of the disease image becomes more and more complete -

not larger and more verbose, but more characteristic, more encompassing of the peculiarity of this collective disease.




33

§102

Upon recording the symptoms of several cases of this kind, the sketch of the disease image becomes more and more complete -

not larger and more verbose, but more characteristic, more encompassing of the peculiarity of this collective disease.

On one hand, the general signs (e.g. , loss of appetite, sleeplessness) obtain their own narrower determinations.



34

§102

Upon recording the symptoms of several cases of this kind, the sketch of the disease image becomes more and more complete -

not larger and more verbose, but more characteristic, more encompassing of the peculiarity of this collective disease.

On one hand, the general signs (e.g. , loss of appetite, sleeplessness) obtain their own narrower determinations.


On the other hand, the more marked, particular, and (at least in this connection) rarer symptoms, belonging to only a few diseases, emerge and form what is characteristic for this epidemic.



35

Genus Epidemicus

the Genus Remedy of (this particular) Epidemic



36



Why a Duck ?

37



Why a Duck ?



Oscilloccoccinum (Anas barbarea hepar et carduus extractum)

38

487 patients were recruited by 149 general practitioners (mostly non-homoeopaths) in the Rhone-Alpes region of France during the influenza epidemic of January-February 1987. Entry criteria were: rectal temperature of 38°C (100.4 F) or above, and at least two of the following symptoms: headache, stiffness, lumbar or articular pain and shivers. The first manifestations had to have occurred less than 24 hours before entry. Patients with immune deficiency, local infection, or who had been immunized against influenza were excluded. Diagnosis was purely clinical, although the A H1N1 influenza virus was subsequently identified as being responsible for the epidemic. Patients were randomly assigned to active Oscilloccoccinum (237 patients) or identical placebo (241 patients), 5 doses at 12 hour intervals. Recovery was defined as temperature less than 37.5°C (99.5 F), with complete resolution of the 5 cardinal symptoms.

#### Results

After 48 hours, 17% of the active treatment group had fully recovered, compared to 10% of the placebo group. This difference was statistically significant ( $p=0.03$ , X2 test). Further analysis showed that the effect of Oscilloccoccinum peaked at 36 hours, when 40% of recoveries were attributable to the treatment. It was most effective in younger patients - 68% of recoveries within 48 hours in the under-30's were due to treatment; and when the illness was relatively mild - 52% of the recoveries from illnesses classified mild or moderate were due to treatment. Patients on active treatment used significantly less other treatment for pain and fever (50% v 41%,  $p=0.04$ ), they also judged the active treatment more efficacious than placebo (61% v 49%  $p=0.02$ ).


The Lancet commented favorably on the trial, remarking that the authors were restrained in their discussion, and describing the difference between placebo and active treatment as 'respectable'. The Lancet's report was 'quadruple-blind' mentioning only at the very end that the treatment was homoeopathic.

Ferley JP, Zmirou D, D'Adhemar D, Balducci F.

A controlled evaluation of a homoeopathic preparation in influenza-like syndromes.

Br J Clin Pharmac (1989) 27, 329-335.


39




<http://www.youtube.com/watch?v=ixxNFnQbQgo>  
(computer audio)

40







41




42



43



44



45

[GENERALS] INFLUENZA: (125) ~~Acon.~~ aesc. all-c. ant-ar. ant-i. ant-t. apis arn. ars. ars-i. ars-s-r. arum-d. asc-c. asc-t. aven. bapt. ~~Bell.~~ Brom. bry. calc. camph. camph-br. canch. capp-erc. carb-ac. carb-v. card-m. caust. cent. cham. chel. chin. Chinin-s. cemic. Cinnb. cupr. cupr-ar. cycl. des-ac. diox. diphtox. dros. dulc. erio. ery-a. Eucal. eug. Eup-per. euph. euphr. ferr-p. Gels. glon. glyc. Graph. gymno. haff. influ. iod. ip. kali-bi. kali-c. kali-i. kali-s. Kreos. lach. lob-c. lob-p. lob-s. lyc. Lycpr. menth. MERC. merc-c. merc-k-i. Nat-n. nat-s. Nat-sal. Nux-v. oci-sa. oscilloc. oxyg. phel. phos. phyt. podo. Psor. puls. pyrog. rad-br. rhus-r. Rhus-t. rumx. sabad. sal-ac. salin. salol. Sang. sangin-n. sanic. sarcol-ac. sarr. seneg. Sil. silphu. spig. spong. squil. stict. still. stram. stry-xyz. sul-i. sulo-ac. Sulph. Thymul. trios. Tub. tub-a. vario. Verat. verat-v. wye. yers. ziz. + (9)

Pace is not Remitting

46

#### [FEVER] REMITTENT: (48)

~~ACON.~~ ant-c. Ant-t. arn. ARS. ars-s-f. bapt. ~~BELL.~~ bol-la. BRY. CHAM. chin. Chinin-s. cina Cocc. coff. coloc. Crot-h. eup-per. ferr. ferr-p. GELS. hyos. ign. Ip. Lach. lept. Lyc. mag-c. mag-s. MERC. mur-ac. Nat-s. nit-ac. Nux-v. Nyct. ph-ac. phos. Podo. polyp-p. puls. rhus-t. sep. stram. Sulph. tarax. tub. verat. + (10)

May Palliate fever -  
do not address the fundamental disease process


47

#### [FEVER] REMITTENT: (48)


~~ACON.~~ ant-c. Ant-t. arn. ARS. ars-s-f. bapt. BELL. bol-la. BRY. CHAM. chin. Chinin-s. cina Cocc. coff. coloc. Crot-h. eup-per. ferr. ferr-p. GELS. hyos. ign. Ip. Lach. lept. Lyc. mag-c. mag-s. MERC. mur-ac. Nat-s. nit-ac. Nux-v. Nyct. ph-ac. phos. Podo. polyp-p. puls. rhus-t. sep. stram. Sulph. tarax. tub. verat. + (10)

Aconite at first signs of fever ?


48



49



50



51

FEVER - SUCCESSION of stages - ...

FEVER - SUCCESSION of stages - chill - accompanied by - heat (70): ... ARS ... bry ... RHUS-t ...

FEVER - SUCCESSION of stages - chill - accompanied by - heat - flushes of heat (4): ... ars ...

FEVER - SUCCESSION of stages - chill - accompanied by - heat - External heat (34): ... Ars ... bry ... kali-bi ... NUX-V

FEVER - SUCCESSION of stages - chill - followed by - heat - then perspiration

FEVER - SUCCESSION of stages - chill - followed by - perspiration - intervening heat; without

FEVER - SUCCESSION of stages - chill - accompanied by - perspiration

GENERALS - PERSPIRATION - during - amel. ... Bry ... Gels ...

GENERALS - PERSPIRATION - during - no relief; gives ... Nux-v ...

52

[GENERALS] INFLUENZA: (125) Acon. aesc. all-c. ant-ar. ant-i. ant-t. apis arn. ars. ars-i. ars-s-r. arum-d. asc-c. asc-t. aven. bapt. Bell. Brom. bry. calc. camph. camph-br. canch. capp-crc. carb-ac. carb-v. card-m. caust. cent. cham. chel. chin. Chinin-s. cimic. Cinnb. cupr. cupr-ar. cycl. des-ac. dioxi. diphtox. dros. dulc. erio. ery-a. Eucal. eug. Eup-per. euph. euphr. ferr-p. Gels. glon. glyc. Graph. gymno. haff. **infl.** iod. ip. kali-bi. kali-c. kali-i. kali-s. Kreos. lach. lob-c. lob-p. lob-s. lyc. Lycpr. menth. MERC. merc-c. merc-k-i. Nat-n. nat-s. Nat-sal. Nux-v. oci-sa. **oscilloc.** oxyg. phel. phos. phyt. podo. Psor. puls. pyrog. rad-br. rhus-r. Rhus-t. rumx. sabad. sal-ac. salin. salol. Sang. sangin-n. sanic. sarcol-ac. sarr. seneg. Sil. silphu. spig. spong. squil. stict. still. stram. stry-xyz. sul-i. sulo-ac. Sulph. Thymul. trios. Tub. tub-a. vario. Verat. verat-v. wye. yers. ziz. + (9)

53

[GENERALS] INFLUENZA: (125) Acon. aesc. all-c. ant-ar. ant-i. ant-t. apis **arn.** **ars.** **ars-i.** ars-s-r. arum-d. asc-c. asc-t. aven. **bapt.** Bell. Brom. **bry.** calc. camph. camph-br. canch. capp-crc. carb-ac. carb-v. card-m. caust. cent. cham. **chel.** chin. Chinin-s. cimic. Cinnb. cupr. cupr-ar. cycl. des-ac. dioxi. diphtox. dros. dulc. erio. ery-a. Eucal. eug. **Eup-per.** euph. euphr. ferr-p. **Gels.** glon. glyc. Graph. gymno. haff. influ. iod. **ip.** **kali-bi.** kali-c. **kali-i.** kali-s. Kreos. lach. lob-c. lob-p. lob-s. lyc. Lycpr. menth. MERC. merc-c. merc-k-i. Nat-n. nat-s. Nat-sal. **Nux-v.** oci-sa. oscilloc. oxyg. phel. phos. phyt. podo. Psor. puls. **pyrog.** rad-br. rhus-r. **Rhus-t.** rumx. sabad. sal-ac. salin. salol. **Sang.** sangin-n. sanic. sarcol-ac. sarr. seneg. Sil. silphu. **spig.** spong. squil. **stict.** still. stram. stry-xyz. sul-i. sulo-ac. Sulph. Thymul. trios. Tub. tub-a. vario. Verat. verat-v. wye. yers. ziz. + (9)

54

[GENERALS] INFLUENZA: (125) Acon. aesc. all-c. ant-ar. ant-i. **ant-t.** apis arn. ars. ars-i. ars-s-r. arum-d. asc-c. asc-t. aven. bapt. Bell. Brom. bry. calc. camph. camph-br. canch. capp-crc. carb-ac. **carb-v.** card-m. **caust.** cent. cham. chel. chin. Chinin-s. cimic. Cinnb. cupr. cupr-ar. cycl. des-ac. dioxi. diphtox. dros. dulc. erio. ery-a. Eucal. eug. Eup-per. euph. euphr. ferr-p. Gels. glon. glyc. Graph. gymno. haff. influ. iod. ip. kali-bi. kali-c. kali-i. kali-s. Kreos. lach. lob-c. lob-p. lob-s. lyc. Lycpr. menth. MERC. merc-c. merc-k-i. Nat-n. nat-s. Nat-sal. Nux-v. oci-sa. oscilloc. oxyg. phel. **phos.** phyt. podo. Psor. **puls.** pyrog. rad-br. rhus-r. Rhus-t. rumx. sabad. sal-ac. salin. salol. **Sang.** sangin-n. sanic. sarcol-ac. sarr. seneg. Sil. silphu. spig. spong. squil. stict. still. stram. stry-xyz. sul-i. sulo-ac. Sulph. Thymul. trios. Tub. **tub-a.** vario. Verat. verat-v. wye. yers. ziz. + (9)

55




Gelsemium sempervirens



Eupatorium perfoliatum

56



57



58

**Generalities**  
 Glands are swollen; or atrophied.  
 Weakness, emaciation - Feels used up.  
 Discharges are COPIOUS, watery, acrid, salty; thick; green or foul.  
 Diffused soreness; after pains; of affected part.  
 Craves motion in open air.  
 Coldness; of painful part in bones.

Worse	Better
Heat.	Motion.
Touch.	Cool air.
Night, Sunset to sunrise.	Open air.
Damp.	
Changing weather.	
Jarring.	


**Mind**  
 Bad temper, Harsh tempered and cruel.  
 Irritable, irascible esp. towards his children; his family.  
 Despondent, Trivial details of life seem insupportable.  
 Nervous, must walk.

**Head**  
 Violent headaches, as if screwed, through sides of head agg. warmth and pressure.  
 Brain feels enlarged.

**Eyes**  
 Puffy, burning, watery; conjunctiva red.  
 Winking is painful.  
 Oedema around.  
 Lower lids twitch.

**Nose**  
 Red, swollen.  
 Coryza; descending, profuse, acrid, hot, watery discharge agg. cool air;  
 with salivation and dyspnoea.  
 Tightness at the root of the nose.  
 Cool, greenish, irritating, discharge from nose.  
 Burning, throbbing in nose and sinuses.  
 Violent sneezing.

**Kali iodatum**  
 Phatak, *Materia Medica*




**Face** - Tight pain at zygomae.  
 Mouth - Salivation.  
 Throat - Dry.

**Respiratory**  
 Larynx feel raw.  
 Whistling asthmatic breathing.  
 Dry bronchitis.  
 Pneumonia.  
 Frothy, greenish, soapsuds like expectoration.  
 Pain from sternum to back.


**Neck and back**  
 Small of the back as if in a vise.  
 Bruised pain in lumbar region agg. sitting bent.

**Fever**  
 Chilly in bones; in painful parts.  
 Heat in evening.  
 Uncovers then chilly; Alternate heat and chilly.  
 (FEVER - ALTERNATING with - perspiration [18])  
 Heat with shudders.  
 Hot and dry, then drenching sweat.  
 Profuse night sweats which amel.

59



60



(Strychnos) Nux-vomica

Gelsemium sempivirens

61



Baptisia tinctoria

Septic states



Arnica montana



Pyrogenium

62



Sticta (Lobaria) pulmonaria

(compare, Sanguinaria)



63

coryza  
bronchial catarrh  
nervous and rheumatic disturbances

general feeling of dullness & lassitude,  
as if a cold were coming on

Rheumatic, Stiffness

painful dry mucous membranes

worse:

Night

Lying down

Motion

Change of temperature

better:

Free discharges

Open air

Head:

Aches before catarrhal discharge appears

Heaviness in forehead

Eyes:

Burning of eyes

Soreness of eyeballs on closing lids or turning eyes

Nose:

Pressure or stuffy fullness at root of nose

Constant need to blow nose, but no discharge

Painful dryness of mucous membranes

Coryza which dries up soon,

forming scabs difficult to dislodge

Throat:

Dry; dropping of mucus posteriorly

Sticta (Lobaria) pulmonaria

Phatak - Materia Medica



Respiratory:

Tickling high up in pharynx

Incessant dry hacking cough prevents sleep, agg. coughing, inspiration;

towards evening when tired

Air passages numb

Bronchitis

Pain from sternum to spine, agg. motion

Neck, Back:

Sore stiff neck; pains to shoulder

Restless hands and feet

Rheumatism

Cold moist limbs

Profuse [copious] sweat on hands

Chorea-like spasms

Sleep:

Sleeplessness from nervousness; from cough

Related:

Sanguinaria


64



irascible  
 despondent  
 lassitude  
 rheumatic  
 catarrh  
 incessant  
 profuse  
 copious

65

irascible  
 despondent  
 lassitude  
 rheumatic  
 catarrh  
 incessant  
 profuse  
 copious



66



67



(Carapichea) ipecacuanha

Bronchospasm (wheezing/asthma)  
 Nausea, vomiting  
 Spasms


68



*Sanguinaria canadensis*

Bronchitis, Pneumonia, prolonged Respiratory complaints following Influenza


69



Antimonium tartaricum



Carbo vegetabilis



Phosphorus

70



*Tuberculinum aviare / avis*

Influenzal bronchitis

71